Clinical Trials Browser

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Targeted Therapy

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Leukemia, Myeloid, Acute, Neoplasm, Residual

Hematologic Neoplasms

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Disease, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Recurrence, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Clinical Trials

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Study of SA+X in the Treatment of Newly Diagnosed AML

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

VAG-3+7-G

TROPHY-15

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Gilteritinib for the Treatment of ALK NSCLC

MRD-positive AML Clinical Study

TARGETALLO

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

SEQUENCE

OGILAR

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

HOVON 156 AML

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

GMCAII

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation